Cresemba
·
- Prescription status not stated
- Antibiotics, antivirals and antifungals taken into the body
- Active substance
- Isavuconazole
- Made by
- Basilea Pharmaceutica Deutschland GmbH
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Powder for concentrate for solution for infusion: Cresemba is indicated in patients from 1 year of age and older for the treatment of invasive aspergillosis mucormycosis in patients for whom amphotericin B is inappropriate (see sections 4.4 and 5.1) Consideration should be given to official guidance on the appropriate use of antifungal agents. Hard capsules: Cresemba hard capsules are indicated in adults and in paediatric patients from 6 years of age for the treatment of invasive aspergillosis mucormycosis in patients for whom amphotericin B is inappropriate (see sections 4.4 and 5.1) Consideration should be given to official guidance on the appropriate use of antifungal agents. Cresemba 40 mg hard capsules are intended to be used for paediatric patients.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
SpainNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Basilea Pharmaceutica Deutschland GmbH |
|---|---|
| Active substance | Isavuconazole |
| Used in | Antibiotics, antivirals and antifungals taken into the body |
| Classification | J02AC05 · Antibiotics, antivirals and antifungals taken into the body |
| Orphan medicine | Yes — designated for a rare disease, according to the register |
| Authorised on | 2015-10-15 |
| Last updated by the regulator | 2025-07-24 |
| EMA product number | EMEA/H/C/002734 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).